Team:ATOMS-Turkiye/asoMain

From 2014.igem.org

(Difference between revisions)
(Undo revision 291760 by Fethional (talk))
Line 95: Line 95:
         <ul>
         <ul>
             <li class="one">
             <li class="one">
-
                 <div><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="tit">Modeling</a><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="lnk"><span><strong>This year, we have carried out a mathematical modeling to understand how our promoter system would react against hypoxia to be able to treat heart problems. To learn more, <a href="http://parts.igem.org/cgi/partsdb/pgroup.cgi?pgroup=iGEM2014&amp;group=ATOMS-Turkiye">Click Here</a></strong></span></a>
+
                 <div><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="tit">Modeling</a><a href="https://2014.igem.org/Team:ATOMS-Turkiye/Modeling" class="lnk"><span><strong>This year, we have carried out a mathematical modeling to understand how our promoter system would react against hypoxia to be able to treat heart problems. To learn more, click here</strong></span></a>
                     <img src="https://static.igem.org/mediawiki/2014/0/03/ATOMS-Modelling1.png" alt="This is the place of Modeling results" width="210" height="220"><b>This is the place of Modeling results...</b>
                     <img src="https://static.igem.org/mediawiki/2014/0/03/ATOMS-Modelling1.png" alt="This is the place of Modeling results" width="210" height="220"><b>This is the place of Modeling results...</b>

Revision as of 22:26, 16 October 2014

Project Abstract

Tissue hypoxia, or ischemia, is the condition that describes the poor conveyance of oxygen and other vital products to body tissues and organs which consequently results tissue death. Up to now, the number one cause of death worldwide is caused by ischemia and related conditions such as heart attack or stroke. It is needed to regard the big picture of the condition in order to solve the problem. In our project, our will is to build two different devices, which work synergistically, to fix these two distinct situations. We decided to use ‘’hypoxia inducible systems” and ‘’reactive oxygen species (ROS) sensitive gene fragments’’. These two receptors will hopefully regulate the release of clot dissolving factors and antioxidant peptides synthesized by our engineered vessel cells. We hope to bring encouraging results in vitro to pave the way of this promising system into the lifesaving remedy method.